Comparative Pharmacology
Head-to-head clinical analysis: DOXEPIN HYDROCHLORIDE versus NORPRAMIN.
Peer-Reviewed Evidence
Head-to-head clinical analysis: DOXEPIN HYDROCHLORIDE versus NORPRAMIN.
DOXEPIN HYDROCHLORIDE vs NORPRAMIN
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Doxepin is a tricyclic antidepressant (TCA) that inhibits the reuptake of serotonin and norepinephrine, thereby increasing their concentrations in the synaptic cleft. It also exhibits potent histamine H1 receptor antagonism, leading to antihistaminic effects, and has anticholinergic, alpha-adrenergic blocking, and anti-serotonergic properties.
Norpramin (desipramine) is a tricyclic antidepressant (TCA) that primarily inhibits the reuptake of norepinephrine, and to a lesser extent serotonin, at the presynaptic neuronal membrane, thereby increasing their concentrations in the synaptic cleft. It also has anticholinergic, antihistaminergic, and alpha1-adrenergic blocking properties.
25-150 mg orally at bedtime; initially 25 mg, may increase gradually to 150 mg. For minor depression: 25-50 mg orally at bedtime.
25 mg orally three times daily; may increase gradually to 150 mg/day in divided doses. Maximum 200 mg/day.
None Documented
None Documented
Terminal elimination half-life: 8-24 hours (mean 15 hours). Steady-state achieved in 3-5 days. Active metabolite nordoxepin has half-life of 31-50 hours.
Terminal half-life: 18-34 hours (mean ~27 hours); clinical context: supports once-daily dosing, but steady-state requires 5-7 days.
Primarily renal (50-60% as metabolites, <5% unchanged). Biliary/fecal: approximately 20-30%.
Primarily renal (70%) as metabolites and unchanged drug; biliary/fecal (30%) as metabolites.
Category C
Category C
Tricyclic Antidepressant
Tricyclic Antidepressant